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OBJECTIVE—Metabolic syndrome (MetS) has been associated
with increased prevalence of aortic valve calcium (AVC) and
with increased progression of aortic stenosis. The purpose of this
study was to determine whether MetS is associated with in-
creased risks for the development of new (“incident”) AVC or for
progression of established AVC as assessed by CT.
RESEARCH DESIGN AND METHODS—The relationships of
MetS or its components as well as of diabetes to risks for
incident AVC or AVC progression were studied among partici-
pants with CT scans performed at baseline and at either year 2 or
year 3 examinations in the Multi-Ethnic Study of Atherosclerosis
(MESA).
RESULTS—Of 5,723 MESA participants meeting criteria for
inclusion, 1,674 had MetS by Adult Treatment Panel III criteria,
whereas 761 had diabetes. Among the 5,123 participants without
baseline AVC, risks for incident AVC, adjusted for time between
scans, age, sex, race/ethnicity, LDL cholesterol, lipid-lowering
medications, and smoking, were increased signiﬁcantly for MetS
(odds ratio [OR] 1.67 [95% CI 1.21–2.31]) or diabetes (2.06
[1.39–3.06]). In addition, there was an increase in incident AVC
risk with increasing number of MetS components. Similar results
were found using the International Diabetes Federation MetS
criteria. Among the 600 participants (10.5%) with baseline AVC,
neither MetS nor diabetes was associated with AVC progression.
CONCLUSIONS—In the MESA cohort, MetS was associated
with a signiﬁcant increase in incident (“new”) AVC, raising the
possibility that MetS may be a potential therapeutic target to
prevent AVC development. Diabetes 58:813–819, 2009
M
etabolic syndrome (MetS) is a collection of
clinical and laboratory abnormalities com-
prised of central adiposity, hypertriglyceride-
mia, low HDL cholesterol, elevated blood
pressure, and/or impaired fasting glucose (1,2). Overall
MetS prevalence has been estimated at 25% in Western
populations (2,3) but is almost certainly increasing as a
consequence of the worldwide epidemic of obesity (4,5).
MetS is associated with both increased prevalence of
coronary atherosclerosis (1,2,6,7) and increased risk for
clinical cardiovascular events (8,9).
Cross-sectional U.S. data show that the prevalence of
MetS increases with age (3), suggesting that MetS might
contribute to risk for diseases with increased prevalence
in the elderly. Examples of these diseases include both
atherosclerosis (10) and calciﬁc aortic valve disease
(CAVD), which has a prevalence of 25% in those older than
age 65 years (11). CAVD is comprised of aortic sclerosis, in
which the valve is calciﬁed and thickened but does not
obstruct left ventricular outﬂow, and aortic stenosis, in
which obstruction to left ventricular outﬂow is present
(12,13). Aortic sclerosis is associated with an 50% in-
crease in cardiovascular events (14), and aortic stenosis is
associated with a 5-year risk of 80% risk for valve replace-
ment surgery or clinical cardiovascular events (15).
Previous studies have shown that the MetS and diabetes
are associated with the presence of coronary artery cal-
cium as assessed by cardiac CT (7). In the Multi-Ethnic
Study of Atherosclerosis (MESA) cohort, in which the
overall MetS prevalence by Adult Treatment Panel (ATP)
III criteria is 21%, not only is MetS associated with
increased prevalence of CT-detected aortic valve calcium
(AVC), but also increased number of MetS features is
associated with increased AVC prevalence (16). Metabolic
syndrome also has been associated with increased pro-
gression of aortic stenosis (17) and accelerated degenera-
tion of bioprosthetic aortic valves (18).
It is not known, however, whether abnormalities in
glucose metabolism/insulin resistance, as typiﬁed by the
clinical syndromes of MetS and diabetes, are associated
with increased likelihood of incident (“new”) AVC or AVC
progression. We sought to evaluate potential associations
of the MetS and diabetes both in the development of
incident AVC as well as in the progression of established
AVC using data from a multi-ethnic cohort of men and
women, MESA.
RESEARCH DESIGN AND METHODS
Study population. The MESA cohort consists of 6,814 men and women, aged
45 to 84 years, recruited from six U.S. communities (Baltimore, MD; Chicago,
IL; Forsyth County, NC; Los Angeles County, CA; northern Manhattan, NY; and
St. Paul, MN) and who were free of clinically evident cardiovascular disease
at the time of enrollment (baseline). The main objective of MESA is to
determine the characteristics of subclinical cardiovascular disease and its
progression. Participants were excluded if they had a history of any of the
following procedures: coronary bypass surgery, balloon angioplasty, heart
valve replacement, pacemaker or deﬁbrillator implantation, or history of any
other cardiac surgery. The study was designed to include the following
self-identiﬁed ethnic groups: whites, African Americans, Hispanics, and Chi-
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described in detail (19). Participants were enrolled between 1 August 2000,
and 30 July 2002. The institutional review boards at all participating centers
approved the study, and all participants gave informed consent.
Questionnaires were used to obtain information about socioeconomic
status, medical history, medication, and tobacco use. Smoking was deﬁned as
current, former, or never. Waist circumference at the umbilicus was measured
to the nearest 0.1 cm using a steel measuring tape (standard 4-ounce tension).
Resting blood pressure was measured three times with participants in the
seated position with a Dinamap model Pro 100 automated oscillometric
sphygmomanometer (Critikon). The average of the last two measurements
was used in this analysis. Total and HDL cholesterol, triglycerides, and
glucose levels were measured from blood samples obtained after a 12-h fast.
LDL cholesterol was calculated with the Friedewald equation (20).
Diabetes and metabolic syndrome. Participants were considered to have
diabetes if they met the following criteria: self-reported history of adult onset
of diabetes, fasting glucose 126 mg/dl or greater, or use of insulin or oral
glucose-lowering medications.
Among those without diabetes, MetS was deﬁned using ATP III (21)–
modiﬁed criteria. These criteria require three or more of the following ﬁve
criteria for MetS diagnosis: large waist circumference (women 88 and men
102 cm); elevated triglycerides (150 mg/dl); low HDL cholesterol (men
40 and women 50 mg/dl); elevated blood pressure (130/85 mmHg or
self-reported use of medications for hypertension); and impaired fasting
glucose (100–125 mg/dl) as deﬁned in the updated American Heart Associa-
tion/National Heart, Lung, and Blood Institute guidelines (1). Results also
were analyzed using the International Diabetes Federation (IDF) deﬁnition of
MetS.
Measurement of aortic valve calcium by CT. AVC was measured using
either electron-beam tomography (three sites) or multidetector CT (three
sites). A total calcium score was determined by summing individual lesion
scores at each anatomic site. Any calciﬁed focus seen extending to the aortic
root was deemed AVC by methodology described previously (22–24). Calciﬁ-
cation involving either the aortic or mitral annuli was not included. AVC score
was assessed in every patient. The calcium score of each lesion was calculated
by multiplying the lesion area by a density factor derived from the maximal
Hounsﬁeld units within this area as described by Agatston (25). The absence
of AVC was deemed a score of 0. Details of the scanning methodology used for
AVC in the MESA study have been reported (23), and the median interscan
variability for Agatston AVC scores within the MESA cohort is 6.4% (23). All
studies were analyzed at the MESA CT reading center at Harbor-UCLA.
To deﬁne AVC progression, a second AVC measurement was performed on
a random selection of half the cohort at exam 2 (September 2002 to January
2004) and on the other half of the cohort at exam 3 (March 2004 to July 2005).
The mean time between scans was 2.4 (0.9) years.
Data analyses. The study population for this analysis includes all MESA
participants who had no missing data on any component of MetS with both
baseline (exam 1) and follow-up (exam 2 or 3) CT scans. After applying these
criteria, 5,723 individuals remained for analysis.
Participants were classiﬁed by the presence or absence of the MetS and
diabetes, creating three groups (diabetes, MetS, and neither condition).
Baseline demographics and laboratory measures were expressed with means
and proportions and compared across groups using the 
2 test and ANOVA.
Because the exact date of development of incident AVC is not known, risk
time was calculated as the elapsed time from the baseline to the second or
third MESA examination. Unadjusted incident AVC rates were calculated as
the number of events divided by person-years at risk, and incident AVC rates
were examined according to the three groups of neither condition, MetS, or
diabetes.
Two end points were created and modeled separately. The primary
outcome of interest was incident progression of AVC deﬁned as detectable
AVC (AVC score 0) at follow-up (either exam 2 or 3) among those with no
AVC (AVC  0) at the baseline examination. This was treated as a dichoto-
mous end point, and yearly incidence rates were calculated among the three
groups. Logistic regression was used to evaluate the association between
incident AVC and the MetS and diabetes groups. Unadjusted analyses were
performed followed by multivariable modeling that included age, ethnicity,
and time between scans. A second adjusted model added LDL cholesterol,
lipid-lowering medication use, smoking status, and scanner type (to account
for scanner changes that were made at some of the sites).
A secondary outcome looked at AVC progression deﬁned as an absolute
change in AVC score among those with detectable AVC at exam 1. The
absolute change was calculated as the difference between AVC score at
follow-up and baseline. This was treated as a continuous end point for which
we found that 62 participants (10.3%) had very large residuals and therefore
used robust linear regression to downweight their inﬂuence (26,27). The same
modeling strategy used for incident AVC, as described, was used for AVC
progression with additional adjustment for baseline AVC score.
We also looked at the number of MetS risk factors while treating diabetes
as a separate category in order to explore relative associations of individual
MetS components and of the number of components with incidence and
progression of AVC using those with 0 MetS risk factors as the reference
group. Because the numbers of participants who had four or ﬁve risk factors
were relatively small, they were grouped together.
Interactions were evaluated between the three groups and each sex as well
as between the three groups and each race. A P value 0.05 was considered
statistically signiﬁcant. Statistical analyses were performed with S-Plus (re-
lease 6.1; Insightful, Seattle, WA) and SPSS 15.0.1 software for Windows
(SPSS, Chicago, IL).
RESULTS
Participant characteristics. The study population for
these analyses included 5,723 MESA subjects with a mean
age of 62 years (SD  10); 52% were female, 27% were
African American, 12% were Chinese, and 22% were His-
panic. Of these, 1,674 (29%) met the ATP III deﬁnition for
MetS and an additional 761 (13%) met the deﬁnition for
diabetes. Table 1 shows the distribution of demographics
and components of the MetS by MetS and diabetes groups.
Participants with neither MetS nor diabetes were more
likely to be younger; have lower values for BMI, triglycer-
ides, and systolic blood pressure; and higher values for
HDL. Large waist circumference was the most common
component for the MetS (83%), whereas high blood pres-
sure was the most common component for diabetes (77%).
Of the 5,123 participants with an AVC of 0 at baseline,
211 (4%) developed an AVC greater than 0 over follow-up
(new “incident” AVC). The breakdown by condition is 88
(3%) for neither MetS nor diabetes, 79 (5%) for MetS, and
44 (7%) for diabetes (P  0.0001). At baseline, there were
600 (11%) participants with AVC greater than 0 who were,
therefore, classiﬁed as at risk for AVC progression. Of
these, 266 (8%) had neither MetS nor diabetes, 204 (12%)
had MetS only, and 130 (17%) had diabetes (P  0.001).
The median baseline AVC score for these 600 participants
was 68 Agatston units (interquartile range [IQR] 25–152).
The median (IQR) baseline AVC scores were, by condition,
54 (22–144) for neither MetS nor diabetes, 80 (25–178) for
MetS, and 63 (27–113) for diabetes (P  0.335).
Incident AVC
Rates for incident AVC by metabolic syndrome,
diabetes, or neither condition. Incident (“new”) AVC
was higher among those with either MetS or diabetes as
compared with those with neither condition. The yearly
rate of incident AVC per 100 person-years (among partic-
ipants without AVC at baseline) in subjects with the MetS
was lower than in those with diabetes (Fig. 1, left). Rates
of incident AVC were 2.2% per year in those with ATP
III–deﬁned MetS and 3.0% per year in those with diabetes
as compared with 1.2% per year in those with neither (P 
0.0001 for ATP III MetS versus neither condition and P 
0.0001 for diabetes versus neither condition). Similar
results were obtained using the IDF criteria for MetS (Fig.
1, right). There was no sex or race interaction for the
relationship of either MetS or diabetes with incident AVC
(P for interaction  0.633 and 0.581, respectively).
Rates of incident AVC by number of MetS components.
There was a graded, linear association between the rate
of incident AVC and the number of MetS components.
Those with diabetes had the highest rates of incident
AVC (Fig. 2).
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AVC. In logistic regression analyses adjusted for age, sex,
ethnicity, and time between scans, the odds ratios (ORs)
for incident AVC were signiﬁcantly higher in participants
with either the MetS (1.73 [95% CI 1.25–2.38]) or diabetes
(2.16 [1.46–3.19]) as compared with those with neither
condition. These associations persisted after additional
adjustment for LDL cholesterol, lipid-lowering medication
use, and smoking (MetS, OR 1.67 [1.21–2.31], and diabetes,
2.06 [1.39–3.06]) (Table 2).
Risks for incident AVC by number of MetS components.
When examining the ORs for incident AVC by number of
MetS components (Fig. 3), a similar pattern emerged. As
compared with those with no MetS components, partici-
pants with three MetS risk factors, four to ﬁve MetS risk
factors, and diabetes had a signiﬁcantly increased risk of
incident AVC in a model adjusted for age, sex, ethnicity,
time between scans, LDL cholesterol, use of lipid-lowering
medication, and smoking (OR, 1.88 [95% CI 1.01–3.51], 2.24
[1.16–4.30], and 2.50 [1.32–4.73], respectively).
Incident AVC and individual MetS components. We
evaluated the association of individual components of the
MetS with incident AVC (Table 3) in those participants
without diabetes. Each of the ﬁve MetS components was
added in the model simultaneously, and the model was
then further adjusted for age, sex, ethnicity, time between
scans, LDL cholesterol, lipid-lowering medication, and
smoking. Incident AVC was only related to low HDL
(adjusted OR 1.54 [95% CI 1.08–2.19]). In both unadjusted
and demographic-adjusted analyses, there were associa-
tions between impaired fasting glucose and incident AVC,
but these associations were attenuated and of marginal
statistical signiﬁcance after multivariable adjustment (1.36
[0.97–1.90]).
Given the strong relationship of AVC among those with
diabetes, we also looked at the association of continuous
glucose (per 10 mg/dl). For participants without diabetes,
the unadjusted model showed a strong increased risk
between glucose and incident AVC (OR 1.33 [95% CI
1.14–1.55]). Although this risk was attenuated after full
adjustment, it remained signiﬁcantly elevated (1.18 [1.01–
1.40]).
AVC progression. Among those with AVC at baseline
(n  600), the median (IQR) annualized rate of AVC score
change was 5.4 (2.0 to 23.0) Agatston units per year. The
rate of AVC score change did not vary signiﬁcantly by
MetS or diabetes status (P  0.341 by Kruskal-Wallis) (Fig.
4). When examining the median AVC change by number of
TABLE 1
Characteristics of participants with diabetes, ATP III–deﬁned MetS, or neither condition
Neither
condition MetS Diabetes P
n 3,288 1,674 761
Age (years) 61  10 63  10 65  9 0.001
Men 1,601 (49) 716 (43) 406 (53) 0.001
Race/ethnicity 0.001
Caucasian 1,440 (44) 677 (40) 151 (20)
Chinese American 428 (13) 151 (9) 95 (13)
African American 823 (25) 435 (26) 285 (38)
Hispanic 597 (18) 411 (25) 230 (30)
Glucose (mg/dl) 93  9 101  10 155  53 0.001
BMI (kg/m
2) 26.5  4.7 30.9  5.2 30.6  5.7 0.001
Total cholesterol (mg/dl) 194  33 196  36 189  39 0.001
HDL cholesterol (mg/dl) 56  15 44  11 46  12 0.001
LDL cholesterol (mg/dl) 118  30 117  31 112  33 0.111
Triglycerides (mg/dl) 93 (68–124) 162 (112–210) 134 (87–199) 0.001
Lipid-lowering medications 393 (12) 326 (20) 206 (27) 0.001
Diastolic blood pressure (mmHg) 71  10 74  10 72  10 0.001
Systolic blood pressure (mmHg) 121  20 133  21 132  21 0.001
Antihypertensive medications 714 (22) 821 (49) 465 (61) 0.001
Current smoker 405 (12) 229 (14) 91 (12) 0.556
Metabolic syndrome components*
Abdominal obesity (large waist) 1,140 (35) 1,393 (83) 518 (68) 0.001
High blood pressure 1,263 (38) 1,301 (78) 584 (77) 0.001
LDL cholesterol 547 (17) 1,119 (67) 385 (51) 0.001
High triglycerides 359 (11) 994 (59) 334 (44) 0.001
Impaired fasting glucose (100–125 mg/dl)† 568 (17) 1,013 (61) 0 (0) 0.001
Data are n (%), means  SD, or means (interquartile range). *At least three of the ﬁve following conditions deﬁne presence of MetS: high
blood pressure, low HDL cholesterol, high triglycerides, impaired fasting glucose, or large waist. †American Diabetes Association deﬁnition
of impaired fasting glucose.
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Kruskal-Wallis, results not shown). Adjusted robust re-
gression also showed that there was no signiﬁcant AVC
progression in Agatston units per year for either the MetS
or diabetes compared with neither condition (results not
shown).
DISCUSSION
Only one prospective study has demonstrated an associa-
tion of MetS with increased risk for prevalent AVC (16),
whereas retrospective studies have demonstrated that
MetS is associated with increased rates of aortic stenosis
progression (17) and bioprosthetic valve deterioration
(18). AVC incidence is more important than prevalent AVC
because it provides stronger evidence in establishing
causality. By separating predictor and outcome variable
over time, the longitudinal analysis reduces systematic
bias and enhances causal inference. The present study is
the ﬁrst to prospectively examine the relationship of MetS
to risks for incident (“new”) AVC and AVC progression. In
fully adjusted analyses, both MetS and the number of MetS
components were associated strongly with increased risk
for incident AVC. We did not, however, identify an asso-
ciation of either MetS or diabetes with the rate of AVC
progression.
The relationship of advanced dysglycemia, that is, clin-
ical diabetes, to aortic valve disease pathology has been
demonstrated in previous small, retrospective studies re-
porting associations of diabetes with increased prevalence
of AVC (28) as well as with increased prevalence (29) and
progression (30) of aortic stenosis. We and others have
extended the relationship of less severe dysglycemia, that
is, MetS, to aortic valve disease pathology by demonstrat-
ing that MetS is associated not only with increased prev-
alence of AVC (16), but also with faster aortic stenosis
progression (17) and more rapid deterioration of biopros-
thetic aortic valves (18). The results of the present study
further extend the relationship of MetS to early-stage
aortic valve disease pathology by demonstrating that MetS
and MetS components are associated with an increased
rate of new (“incident”) AVC. In our study, participants
with diabetes and the MetS had the highest prevalence of
new (“incident”) AVC.
The association of the dysglycemias, including diabetes
and MetS, with increased risks for prevalent vascular (6,7)
and valvular (16) calciﬁcation has been established, and
interesting studies have begun to elucidate potential mech-
anisms that may underlie these associations. The key
osteogenic regulatory factor, bone morphogenic protein
(BMP)2, is upregulated by hyperglycemia in vitro. (31,32)
BMP2 has been demonstrated to play a role in vascular
calciﬁcation (33,34) and has been detected in areas of
valvular calciﬁcation (35). BMP2 upregulates both “osteo-
genic” differentiation regulated by the transcription factor
Msx2 and “chondro-ostegenic” differentiation regulated by
the transcription factor Runx2/Cbfa1 (36).
Diabetes is characterized by a pro-oxidant state (37,38).
Not only are oxidized lipoproteins present in human aortic
valve lesions (39), but oxidized lipids also have been
shown to upregulate the rate of calcium nodule formation
in valvular cells in vitro (40). Several potential mecha-
FIG. 2. Rates of incident AVC by number of MetS components as
deﬁned by ATP III criteria (A) or IDF criteria (B). DM, diabetes.
TABLE 2
Logistic regression models for the risk of incident AVC (among
those free of AVC at baseline) and diabetes, MetS (by ATP III
criteria), or neither condition
Neither
condition MetS Diabetes
n 3,022 1,470 631
Unadjusted 1.0 (ref.) 1.84 (1.35–2.53) 2.54 (1.75–2.53)
Adjusted* 1.0 (ref.) 1.73 (1.25–2.38) 2.16 (1.46–3.19)
Adjusted† 1.0 (ref.) 1.67 (1.21–2.31) 2.06 (1.39–3.06)
Data are OR (95% CI). *Adjusted for time between scans, age, sex,
and race/ethnicity. †Adjusted for time between scans, age, sex,
race/ethnicity, scanner type, LDL cholesterol, lipid-lowering medica-
tions, and smoking.
FIG. 3. Adjusted ORs (boxes) and corresponding 95% CIs (bars) for
incident AVC by number of ATP III MetS criteria or diabetes (DM).
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seen with metabolic syndrome and diabetes.
These observational ﬁndings also are interesting in light
of the recent demonstration that an elevated total-to-HDL
cholesterol ratio is associated with a consistent increase in
relative risk for AVC across all ages in the MESA cohort
(41). Clinical abnormalities of glucose metabolism (which
include impaired fasting glucose, impaired glucose toler-
ance, and type 2 diabetes) are associated with both a
progressive increase triglyceride-rich VLDL cholesterol
and a progressive decrease in HDL cholesterol (8). To-
gether, these changes increase the total-to-HDL choles-
terol ratio (42). Retrospective studies had suggested a
potential beneﬁt of statin therapy (which primarily lowers
LDL levels) in aortic valve disease (43–46). The results of
subsequent, properly controlled clinical trials of atorvasta-
tin (47) or of simvastatin plus ezetimibe (48) have been
convincingly negative despite average therapy-related LDL
reductions of over 50% in both trials. Because the charac-
teristic MetS lipid abnormalities of high triglycerides and
low HDL result in an increase in the total-to-HDL choles-
terol ratio, it is not known whether more speciﬁcally
targeting this MetS-associated dyslipidemia might repre-
sent an effective strategy for decreasing the MetS-associ-
ated risks for incident AVC.
Recent studies have implicated the renin-angiotensin
system, which is upregulated in MetS (2) in aortic valve
disease pathogenesis (49–52). Retrospective studies of
ACE inhibitor therapy have been mixed in the general
population of individuals with aortic sclerosis (50) or
aortic stenosis (46). The results of the present study,
however, raise the possibility that renin-angiotensin sys-
tem inhibitor therapy targeted to those with MetS might
prove effective at slowing the rate of development of
CAVD.
The association of progressive increase in plasma glu-
cose with progressive increase in risk for incident AVC
risk raises the possibility that dysglycemia may represent
an additional therapeutic target in this disease, as has been
demonstrated for atherosclerosis (53).
This study has limitations, which include the possibility
of survival bias, because those with clinical cardiovascular
disease were excluded from MESA; limited statistical
power, because the exclusion of those with known cardio-
vascular disease from MESA may have also resulted in the
exclusion of individuals with MetS (1,2) and AVC (16),
thereby limiting our power to show a relationship between
MetS and AVC progression; dichotomization of continuous
measures such as MetS components, which may decrease
available information and result in misclassiﬁcation of
exposure; and survival bias attributed to participants who
did not attend the follow-up examinations; and given the
relatively short follow-up time, it is possible that AVC may
not have developed between visits or AVC may not have
been captured by CT scans. Nonetheless, MetS is deﬁned
using cut points in clinical practice. It is reassuring that
similar results were found using both ATP III and IDF
MetS criteria. Strengths of this study include use of a large,
well-characterized, population-based cohort and of a
highly reproducible technique for quantifying AVC.
This study formally tests the hypothesis that MetS is
associated with increased risk for the development of
AVC. These ﬁndings further underscore the clinical impor-
tance of identifying MetS in populations without clinical
cardiovascular disease and, further, raise the possibility of
screening for the presence of aortic valve disease in those
with MetS. These ﬁndings suggest that future studies
targeting the MetS-associated “atherogenic dyslipidemia”
of high triglycerides and low HDL cholesterol as well as
renin-angiotensin system components and/or insulin resis-
tance may identify useful strategies to decrease the devel-
opment of aortic valve disease.
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TABLE 3
Logistic regression models for the risk of incident AVC (among those free of AVC at baseline) for each component of the MetS in
participants free of diabetes
OR (95% CI)
Adjusted* Adjusted† Adjusted‡
Elevated blood pressure 1.37 (0.96–1.95) 1.34 (0.94–1.91) 1.25 (0.87–1.79)
LDL cholesterol 1.64 (1.18–2.28) 1.63 (1.17–2.27) 1.54 (1.08–2.19)
High triglycerides 1.25 (0.87–1.80) 1.22 (0.85–1.76) 0.96 (0.65–1.42)
Impaired fasting glucose (100 mg/dl) 1.53 (1.10–2.12) 1.49 (1.07–2.07) 1.36 (0.97–1.90)
Abdominal obesity 1.41 (1.00–1.99) 1.39 (0.98–1.96) 1.20 (0.83–1.72)
*Adjusted for time between scans, age, sex, and race/ethnicity. †Adjusted for time between scans, age, sex, race/ethnicity, scanner type, LDL
cholesterol, lipid-lowering medications, and smoking. ‡Adjusted further for components of the MetS.
FIG. 4. Median AVC change by diabetes, MetS, or neither condition.
“Box” plots the median AVC progression score (middle horizontal
lines) in Agatston units/year and corresponding 25th (lower bound of
box) and 75th (upper bound of box) percentile ranges.
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